Safer, more effective treatment for ischemic stroke is urgently needed. Most patients (80%) are ineligible for current therapy and 70% of patients that receive treatment still have enduring disability.
Ischemic stroke is caused by a blood clot in a brain artery. It is a leading cause of disability in the US and worldwide. Annual stroke-related medical and disability costs are projected to nearly triple by 2030.
Novel, effective treatment strategies could alleviate suffering and disability, and save billions of dollars annually. TS23 dissolves blood clots by inactivating a2-antiplasmin. a2-inactivation reduces brain injury, bleeding, disability and death in experimental ischemic stroke. A Phase II clinical trial will evaluate the safety and efficacy of TS23 for treatment of ischemic stroke.
Safe dissolution of pulmonary emboli may prevent serious, disabling complications and death.
Pulmonary embolism is caused by blood clots in the lungs. Pulmonary embolism affects millions of patients each year and is a leading cause of hospital deaths. Pulmonary emboli may seriously obstruct blood flow to cause right heart failure, circulatory collapse and death within hours or days. Anticoagulation treatment does not dissolve these clots.
TS23 dissolves blood clots in experimental pulmonary embolism and does not cause bleeding. TS23 is entering Phase II trials for the treatment of patients with pulmonary embolism.